【RCT】確立されたアテローム動脈硬化性心血管疾患患者へのアスピリン81mg投与は、325mg投与と比較して、複合転帰(全原因死亡、心筋梗塞による入院や脳卒中による入院)および大出血による入院に差がなかった。 #ペ読 https://t.co/0AjHQk8B05
ADAPTABLE trial: In Pts with CAD, no difference between ASA 81 mg/d and 325 mg/d for all-cause death/MI/stroke or major bleeding at 26.2 months. More discontinuation and dose switching to 81 mg/d in the 325 mg/d group. https://t.co/q8qD2ffxtF https://t.co
RT @rafabravo: Pues parece que lo de los 300 mg de aspirina no son necesarios. https://t.co/t5gUNkNtBW Mira que ha costado convencer a alg…
RT @DrSamuelBrown: Pragmatic trials are important to do and require considerable work to interpret. That's okay. Proud that @Research_Inter…
RT @kaz_yos: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/CKeARbvuRT https://t.co/76Aj2xITRn
RT @DrSamuelBrown: Pragmatic trials are important to do and require considerable work to interpret. That's okay. Proud that @Research_Inter…
RT @DrSamuelBrown: Pragmatic trials are important to do and require considerable work to interpret. That's okay. Proud that @Research_Inter…
RT @DrSamuelBrown: Pragmatic trials are important to do and require considerable work to interpret. That's okay. Proud that @Research_Inter…
Pragmatic trials are important to do and require considerable work to interpret. That's okay. Proud that @Research_Inter and @KirkKnowlton were able to contribute to this important effort. https://t.co/vf8O5fKm3N
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/CKeARbvuRT https://t.co/76Aj2xITRn
RT @rafabravo: Pues parece que lo de los 300 mg de aspirina no son necesarios. https://t.co/t5gUNkNtBW Mira que ha costado convencer a alg…
RT @Susumu_Manabe: アスピリンは81mgでも325mgでも心血管イベント予防効果に差はない。15,076例を対象にした無作為化比較試験の結果。 https://t.co/WmrSN5DNI7 https://t.co/rw3D77oY9T
RT @EricTopol: New @NEJM #ACC21 What's the right dose of aspirin for people with heart disease? A large randomized trial with a lot of cro…
RT @Susumu_Manabe: アスピリンは81mgでも325mgでも心血管イベント予防効果に差はない。15,076例を対象にした無作為化比較試験の結果。 https://t.co/WmrSN5DNI7 https://t.co/rw3D77oY9T
RT @Susumu_Manabe: アスピリンは81mgでも325mgでも心血管イベント予防効果に差はない。15,076例を対象にした無作為化比較試験の結果。 https://t.co/WmrSN5DNI7 https://t.co/rw3D77oY9T
アスピリンは81mgでも325mgでも心血管イベント予防効果に差はない。15,076例を対象にした無作為化比較試験の結果。 https://t.co/WmrSN5DNI7 https://t.co/rw3D77oY9T
RT @AmiBhattMD: Small but fierce: Does 81mg win? Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.c…
RT @pamaris: Dosis de aspirina en prevención secundaria. Estudio clínico aleatorizado pragmático (condiciones de mundo real). En pacientes…
RT @osmachope: No hay diferencia en seguridad y resultados entre AAS 81 y 325mg @NEJM https://t.co/wH8hdLM8XC
Dosis de aspirina en prevención secundaria. Estudio clínico aleatorizado pragmático (condiciones de mundo real). En pacientes con ECV aterosclerótica establecida, 81 mg/día de tiene eficacia similar a 325 mg/día; pero adherencia es mayor con 81 mg/día. En:
RT @AmiBhattMD: Small but fierce: Does 81mg win? Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.c…
Small but fierce: Does 81mg win? Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/vdBA2cLpYs @pnatarajanmd @hmkyale @keaglemd @DLBHATTMD @ACCinTouch @rwyeh @MGHHeartHealth @NEJM
RT @osmachope: No hay diferencia en seguridad y resultados entre AAS 81 y 325mg @NEJM https://t.co/wH8hdLM8XC
RT @osmachope: No hay diferencia en seguridad y resultados entre AAS 81 y 325mg @NEJM https://t.co/wH8hdLM8XC
No hay diferencia en seguridad y resultados entre AAS 81 y 325mg @NEJM https://t.co/wH8hdLM8XC
RT @Office_j: 【SPRINT3年延長観察/ NEJM】 高リスクHTN 9361ランダム化、3.26年観察後、オープン化3.33年延長観察:「積極」降圧群のSBP平均は127mmHg、「通常」群は137。延長観察期間中の「積極」群「CV死亡・脳卒中・心イベント」…
RT @Office_j: 【SPRINT3年延長観察/ NEJM】 高リスクHTN 9361ランダム化、3.26年観察後、オープン化3.33年延長観察:「積極」降圧群のSBP平均は127mmHg、「通常」群は137。延長観察期間中の「積極」群「CV死亡・脳卒中・心イベント」…
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/4IB7xX2zlZ
RT @Office_j: 【SPRINT3年延長観察/ NEJM】 高リスクHTN 9361ランダム化、3.26年観察後、オープン化3.33年延長観察:「積極」降圧群のSBP平均は127mmHg、「通常」群は137。延長観察期間中の「積極」群「CV死亡・脳卒中・心イベント」…
RT @Office_j: 【SPRINT3年延長観察/ NEJM】 高リスクHTN 9361ランダム化、3.26年観察後、オープン化3.33年延長観察:「積極」降圧群のSBP平均は127mmHg、「通常」群は137。延長観察期間中の「積極」群「CV死亡・脳卒中・心イベント」…
【SPRINT3年延長観察/ NEJM】 高リスクHTN 9361ランダム化、3.26年観察後、オープン化3.33年延長観察:「積極」降圧群のSBP平均は127mmHg、「通常」群は137。延長観察期間中の「積極」群「CV死亡・脳卒中・心イベント」HRは0.87 [95%CI 0.59-1.27]。絶対差は0.35%/年。 https://t.co/zgXOwXl5v1 https://t.co/FTI9udPB0d
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/YoaWVSIV0K
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/E7zleEW93R
(NEJM) Eficacia de las dosis bajas de aspirina https://t.co/LcHYDIsVL4
RT @academicaorta: Important pragmatic trial comparing ASA81 to ASA325 demonstrating no significant benefit of the higher dose. Love trials…
RT @academicaorta: Important pragmatic trial comparing ASA81 to ASA325 demonstrating no significant benefit of the higher dose. Love trials…
RT @Dra_TeraizaMesa: RT @dronita_de: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/ZrZp1bPRRV…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease - PubMed https://t.co/k1sa7fxkMU
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @AparajitaSingh0: “no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg & those assi…
RT @syuichiao89: アスピリン1日81 mgに割り付けられた患者とアスピリン1日325 mgに割り付けられた患者との間で,心血管イベントや大出血に有意な差は認められなかった Comparative Effectiveness of Aspirin Dosing…
アスピリン1日81 mgに割り付けられた患者とアスピリン1日325 mgに割り付けられた患者との間で,心血管イベントや大出血に有意な差は認められなかった Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://t.co/4GrEktyPbE
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @Dra_TeraizaMesa: RT @dronita_de: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/ZrZp1bPRRV…
RT @Dra_TeraizaMesa: RT @dronita_de: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/ZrZp1bPRRV…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
@stephensenn How would Aristotle handle the results of the ADAPTABLE trial? https://t.co/BgT5TKLoO1
RT @FarmaMadridAP: (NEJM) Efectividad comparativa de la dosificación de aspirina en enfermedades cardiovasculares. No hubo diferencias sign…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
Less is more. @XavierPrida Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/4P4OF49OEF
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
RT @aayshacader: "Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register:…
"Best of ACC" a recap of major trials & guidelines from #ACC21 🗓️Join us tomorrow 19th May ⏲️1900 CET @isfteh Register: https://t.co/lYfITVDGwN 🪑@ALEX_MISCHIE @ErinMichos 🗣️ @iamritu @mirvatalasnag @rafavidalperez @biljana_parapid @KTamirisaMD @Dr
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
Hilazo de las novedades en el #ACC21
RT @cpgale3: In patients with established #cardiovascular disease (& with substantial dose switching to 81mg), there was no significant dif…
Great summary of some LBCT @ #ACC21 by @aayshacader -kudos.
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
Great quick fire thread of #ACC21 late breakers
RT @FarmaMadridAP: (NEJM) Efectividad comparativa de la dosificación de aspirina en enfermedades cardiovasculares. No hubo diferencias sign…
Pues parece que lo de los 300 mg de aspirina no son necesarios. https://t.co/t5gUNkNtBW Mira que ha costado convencer a algunos
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
(NEJM) Efectividad comparativa de la dosificación de aspirina en enfermedades cardiovasculares. No hubo diferencias significativas en los eventos CV o hemorragia mayor entre los pacientes asignados a 81 mg y los asignados a 325 mg de aspirina al día https:
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
(NEJM) Efectividad comparada de 2 dosis de ácido acetilsalicílico en la prevención 2ª CV (81 vs 325 mg/día) https://t.co/avLGQqO3bQ ECA https://t.co/z83w4NGSGP
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @Dra_TeraizaMesa: RT @dronita_de: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/ZrZp1bPRRV…
RT @Dra_TeraizaMesa: RT @dronita_de: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/ZrZp1bPRRV…
In patients with established #cardiovascular disease (& with substantial dose switching to 81mg), there was no significant differences in cardiovascular events or major bleeding between assigned trial arms of 81mg & 325mg of aspirin daily. #wondrme
Masterpiece summary #ACC21